The Weill Cornell Medicine Institutional Review Board (WCM-IRB) is an appropriately constituted group whose primary responsibility is to ensure that the rights and welfare of human subjects in research are protected. In doing so, the IRB must ensure all human subject research activities are conducted ethically, and in compliance with Federal regulations, the requirements of applicable New York State and local laws, and institutional policies and procedures. In accordance with the Common Rule and FDA regulations, the IRB has responsibility for approving, modifying, and/or disapproving human subject research. The IRB also has the authority to suspend or terminate research in order to protect research subjects and for noncompliance with applicable rules and regulations.
As part of the IRB’s partnership with the research community in the ethical conduct of human subjects research, this website acts as the entry point to IRB resources at Weill Cornell Medicine.
Please read the entire announcement here
Register here for our upcoming Q&A Session:
WCM is requiring that industry-initiated and -funded trials with a commercial IRB designated by the industry sponsor use that commercial IRB (e.g., WCG, Advarra, BRANY).
If an industry-initiated and -funded trial does not have a designated IRB, it will be sent to BRANY.
Please read our most recent update from Melissa Epstein, Executive Director here.